1Schipper NGM ,Verhoef J, Romeijn SG, et al.Absorption enhancers in nasal insulin delivery and their influence on nasal ciliary functioning[J]. J Control release, 1992,(21): 173.
2Willam A, Blair A,Thomas W,et al.Intranasal bioavailability of insulin powder formulationseffect of permeation enhancer-to -protein ratio[J].J Pharm Sci, 1991,80(8): 725.
4Schipper NG,Romeijn SG, Verboef JC, et al.Nasal insulin delivery with dimethyl-beta-cyclodextrin as an absorption enhancer in rabbits:powder more effective than liquid formulations[J].Pharm Res, 1993 May, 10(5):682.
5Pillion DJ, Amsden JA, Kensil CR, et al.Structure-function relationship among Quillaja Saponins serving as excipients for nasal and ocular delivery of insulin[J].J Pharm Sci, 1996 May, 85(5) : 518.
6Takenaga M, Setizawa Y, Azechi Y, et al.mieroparticle resins as a potential nasal drug delivery sysrem for insulin[J].J Controlled Rlease, 1998 Mar 2,52(1-2):81.
7Ando T, Maitaimi Y, Yamamoto T,et al.Nasal insulindelivery in rabbits using soybeanderived, sterylglucoside and sterol mixtures as novel enhancers in suspansion dosage forms[J].Biol Pharm Bull, 1998 Aug,21(8) :862.
2Pearson T L. Practical aspects of insulin pen devices[J]. Diabetes Sci Technol, 2010, 4( 3 ): 522.
3Breslin S D, Ignaut D A, Boyd D E. Lessons leanaed during the de- velopment of HumaPen MemoirTM, an insulin pen with a memory feature[J]. J Diabetes Sci Technol, 2010, 4(3 ): 540.
4Olsovsky J. Modem technologies in diabetology. CSII(continuous subcutaneous insulin infusion) and CGM (continuous glucose monitoring) in clinical practice[J]. Vnitr Lek, 2011, 57( 11 ):919.
5Matejko B, Cyganek K, Katra B, et al. Insulin pump therapy is e- qually effective and safe in elderly and young type 1 diabetes pa- tients[J]. Rev Diabet Stud, 2011, 8( 2):255.
6Castorino K, Paband R, Zisser H, et al. Insolin pumps in pregnancy: using technology to achieve normoglycemia in women with diabetes [J]. Curr Diab Rep, 2012, 2( 1 ):53.
7Yang M, Dong J, Liu H, et al. Effects of short-term continuous fac- tor-21 levels in patients with newly diagnosed type 2 diabetes mel- litus[J]. PLoS One, 2011, 6( 10): e26359.
8Depreter E~ Burniat A, Blocklet D, et al. Comparative pharma- coscintigraphic and pharmacokinetic evaluation of two new formu-lations of inh~ed insulin in type 1 diabetic: patients[J]. Eur J Phann Biopharm, 2012, 80( 1 ):4.
9Raskin P, Hetler S, Honka M, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled technosphere in- sulin or usual antidiabetes treatment: a randomized trial[J]. Diabetes Obes Metab, 2012, 14(2 ):163.
10Heinemann L. New ways of insulin delivery[J]. Int J Clin Pract Sup- p1, 2011 ( 170):31.
